Dermatology

Pulmonology

Questions discussed in this category

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

2 Answers available

Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?

1 Answer available

What approaches can we take to initiate therapy and improve survival rates in patients with HLH?

1 Answer available

What is your approach for disease activity monitoring in patients with sarcoidosis?

1 Answer available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

2 Answers available

Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?

3 Answers available

Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?

6 Answers available

What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?

2 Answers available

How would you manage subclinical ILD associated with MDA-5 Dermatomyositis?

Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?

1 Answer available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?

Would you change rituximab maintenance dose or schedule?

1 Answer available

How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?

1 Answer available

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

1 Answer available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

2 Answers available

How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?

1 Answer available

What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?

1 Answer available

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

2 Answers available

Papers discussed in this category

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Kidney international reports, 2018-03

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

Rheumatology (Oxford),

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Ann Intern Med,

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Ann Rheum Dis, 2011 Nov 29

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Respir Med, 2012 Apr 09

The treatment of pulmonary sarcoidosis.

Am J Respir Crit Care Med,

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Dermatology

Pulmonology

Questions discussed in this category

Papers discussed in this category

Related Topics in Dermatology